Ocugen, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US67577C1053
USD
1.24
0.01 (0.81%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Protalix Biotherapeutics, Inc.
Esperion Therapeutics, Inc.
Nektar Therapeutics
Ocugen, Inc.
Annexon, Inc.
Talaris Therapeutics, Inc.
Oramed Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Reviva Pharmaceuticals Holdings, Inc.
Calidi Biotherapeutics, Inc.
Ocean Biomedical, Inc.

Why is Ocugen, Inc. ?

1
The company has declared negative results for the last 4 consecutive quarters
  • NET SALES(HY) At USD 1.34 MM has Grown at -40.31%
  • INTEREST(HY) At USD 2.65 MM has Grown at 190.04%
  • OPERATING CASH FLOW(Y) Lowest at USD -59.4 MM
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 13.76%, its profits have fallen by -25.5%
3
Underperformed the market in the last 1 year
  • The stock has generated a return of 13.76% in the last 1 year, much lower than market (S&P 500) returns of 25.41%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ocugen, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Ocugen, Inc.
13.76%
-0.24
82.39%
S&P 500
25.41%
1.92
13.25%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
39.96%
EBIT Growth (5y)
-202.28%
EBIT to Interest (avg)
-54.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
24.21%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-50.42
EV to EBIT
-9.93
EV to EBITDA
-10.39
EV to Capital Employed
-574.49
EV to Sales
141.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(HY)

Higher at USD -36.88 MM

RAW MATERIAL COST(Y)

Fallen by -60.85% (YoY

-24What is not working for the Company
NET SALES(HY)

At USD 1.34 MM has Grown at -40.31%

INTEREST(HY)

At USD 2.65 MM has Grown at 190.04%

OPERATING CASH FLOW(Y)

Lowest at USD -59.4 MM

NET PROFIT(HY)

At USD -36.88 MM has Grown at -26.18%

ROCE(HY)

Lowest at -660%

CASH AND EQV(HY)

Lowest at USD 50.43 MM

DEBT-EQUITY RATIO (HY)

Highest at 24.82 %

OPERATING PROFIT(Q)

Lowest at USD -17.25 MM

Here's what is working for Ocugen, Inc.

Net Profit
Higher at USD -36.88 MM
than preceding 12 month period ended Mar 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Raw Material Cost
Fallen by -60.85% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ocugen, Inc.

Net Sales
At USD 1.34 MM has Grown at -40.31%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Interest
At USD 2.65 MM has Grown at 190.04%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Profit
At USD -36.88 MM has Grown at -26.18%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD -59.4 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit
Lowest at USD -17.25 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Cash and Eqv
Lowest at USD 50.43 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at 24.82 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio